Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 3701385, 14 pages
https://doi.org/10.1155/2017/3701385
Research Article

FTY720 Attenuates Angiotensin II-Induced Podocyte Damage via Inhibiting Inflammatory Cytokines

1Department of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China
2First School of Clinical Medicine, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China

Correspondence should be addressed to Cheng Chen

Received 20 October 2016; Revised 8 December 2016; Accepted 26 December 2016; Published 7 February 2017

Academic Editor: Yong Wu

Copyright © 2017 Ke Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. López-Novoa, A. B. Rodríguez-Peña, A. Ortiz, C. Martínez-Salgado, and F. J. López Hernández, “Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications,” Journal of Translational Medicine, vol. 9, article 13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Tan, X. Wen, and Y. Liu, “Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signaling,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1741–1752, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Segerer, P. J. Nelson, and D. Schlöndorff, “Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies,” Journal of the American Society of Nephrology, vol. 11, no. 1, pp. 152–176, 2000. View at Google Scholar · View at Scopus
  4. C. Guijarro and J. Egido, “Transcription factor-κB (NF-κB) and renal disease,” Kidney International, vol. 59, no. 2, pp. 415–424, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Gorriz and A. Martinez-Castelao, “Proteinuria: detection and role in native renal disease progression,” Transplantation Reviews, vol. 26, no. 1, pp. 3–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Maceyka, K. B. Harikumar, S. Milstien, and S. Spiegel, “Sphingosine-1-phosphate signaling and its role in disease,” Trends in Cell Biology, vol. 22, no. 1, pp. 50–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. T. Kunkel, M. MacEyka, S. Milstien, and S. Spiegel, “Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond,” Nature Reviews Drug Discovery, vol. 12, no. 9, pp. 688–702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Aarthi, M. A. Darendeliler, and P. N. Pushparaj, “Dissecting the role of the S1P/S1PR axis in health and disease,” Journal of Dental Research, vol. 90, no. 7, pp. 841–854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Hänel, P. Andréani, and M. H. Gräler, “Erythrocytes store and release sphingosine 1-phosphate in blood,” FASEB Journal, vol. 21, no. 4, pp. 1202–1209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Pappu, S. R. Schwab, I. Cornelissen et al., “Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate,” Science, vol. 316, no. 5822, pp. 295–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. W. L. Santos and K. R. Lynch, “Drugging sphingosine kinases,” ACS Chemical Biology, vol. 10, no. 1, pp. 225–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Hla, M.-J. Lee, N. Ancellin et al., “Sphingosine-1-phosphate: extracellular mediator or intracellular second messenger,” Biochemical Pharmacology, vol. 58, no. 2, pp. 201–207, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Kono, Y. Mi, Y. Liu et al., “The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis,” The Journal of Biological Chemistry, vol. 279, no. 28, pp. 29367–29373, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Rosen, R. C. Stevens, M. Hanson, E. Roberts, and M. B. A. Oldstone, “Sphingosine-1-phosphate and its receptors: structure, signaling, and influence,” Annual Review of Biochemistry, vol. 82, pp. 637–662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Zhang, J. J. A. Contos, J. A. Weiner, N. Fukushima, and J. Chun, “Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate,” Gene, vol. 227, no. 1, pp. 89–99, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Ishii, B. Friedman, X. Ye et al., “Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP B3/EDG-3,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33697–33704, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. C. H. Liu and T. Hla, “The mouse gene for the inducible G-protein-coupled receptor edg-1,” Genomics, vol. 43, no. 1, pp. 15–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Liu, R. Wada, T. Yamashita et al., “Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation,” The Journal of Clinical Investigation, vol. 106, no. 8, pp. 951–961, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Imasawa, H. Kitamura, R. Ohkawa, Y. Satoh, A. Miyashita, and Y. Yatomi, “Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy,” Experimental and Toxicologic Pathology, vol. 62, no. 1, pp. 53–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Zhu, M. Xia, Z. Wang, P.-L. Li, and N. Li, “A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate,” American Journal of Physiology—Renal Physiology, vol. 301, no. 1, pp. F35–F41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Birgbauer and J. Chun, “New developments in the biological functions of lysophospholipids,” Cellular and Molecular Life Sciences, vol. 63, no. 23, pp. 2695–2701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Gardell, A. E. Dubin, and J. Chun, “Emerging medicinal roles for lysophospholipid signaling,” Trends in Molecular Medicine, vol. 12, no. 2, pp. 65–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Brinkmann, “Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology,” Pharmacology and Therapeutics, vol. 115, no. 1, pp. 84–105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. M. Perry, L. Huang, H. Ye et al., “Endothelial sphingosine 1-phosphate receptor-1 mediates protection and recovery from acute kidney injury,” Journal of the American Society of Nephrology, vol. 27, no. 11, pp. 3383–3393, 2016. View at Publisher · View at Google Scholar
  25. A. S. Awad, H. Ye, L. Huang et al., “Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney,” American Journal of Physiology—Renal Physiology, vol. 290, no. 6, pp. F1516–F1524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-H. H. Lien, K.-C. Yong, C. Cho, S. Igarashi, and L.-W. Lai, “S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure,” Kidney International, vol. 69, no. 9, pp. 1601–1608, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Brinkmann, M. D. Davis, C. E. Heise et al., “The immune modulator FTY720 targets sphingosine 1-phosphate receptors,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21453–21457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Ni, J. Chen, M. Pan et al., “FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease,” Journal of Molecular Histology, vol. 44, no. 6, pp. 693–703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. O. J. David, J. M. Kovarik, and R. L. Schmouder, “Clinical pharmacokinetics of fingolimod,” Clinical Pharmacokinetics, vol. 51, no. 1, pp. 15–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. H. Gräler and E. J. Goetzl, “The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors,” The FASEB Journal, vol. 18, no. 3, pp. 551–553, 2004. View at Google Scholar · View at Scopus
  31. H. Müller, S. Hofer, N. Kaneider et al., “The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells,” European Journal of Immunology, vol. 35, no. 2, pp. 533–545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. K. A. Vora, E. Nichols, G. Porter et al., “Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement,” Journal of Leukocyte Biology, vol. 78, no. 2, pp. 471–480, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Kimura, A. M. Boehmler, G. Seitz et al., “The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells,” Blood, vol. 103, no. 12, pp. 4478–4486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Kitabayashi, M. Isobe, N. Watanabe, J.-I. Suzuki, Y. Yazaki, and M. Sekiguchi, “FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes,” Journal of Cardiovascular Pharmacology, vol. 35, no. 3, pp. 410–416, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Fujino, N. Funeshima, Y. Kitazawa et al., “Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 1, pp. 70–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kurose, E. Ikeda, M. Tokiwa, N. Hikita, and M. Mochizuki, “Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats,” Experimental Eye Research, vol. 70, no. 1, pp. 7–15, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Keul, M. Tölle, S. Lucke et al., “The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 607–613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Montalban, G. Comi, P. OConnor et al., “Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study,” Multiple Sclerosis Journal, vol. 17, no. 11, pp. 1341–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. J. Hoitsma, E. S. Woodle, D. Abramowicz, P. Proot, and Y. Vanrenterghem, “FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study,” Nephrology Dialysis Transplantation, vol. 26, no. 11, pp. 3802–3805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Ishii, J. G. Egen, F. Klauschen et al., “Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis,” Nature, vol. 458, no. 7237, pp. 524–528, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Kikuta, K. Iwai, Y. Saeki, and M. Ishii, “S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis,” Rheumatology International, vol. 31, no. 7, pp. 967–969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Chen, Z. Ren, W. Liang et al., “c-Abl mediates angiotensin II-induced apoptosis in podocytes,” Journal of Molecular Histology, vol. 44, no. 5, pp. 597–608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. Z. Ren, W. Liang, C. Chen, H. Yang, P. C. Singhal, and G. Ding, “Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1,” Cellular Signalling, vol. 24, no. 2, pp. 443–450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Sheryanna, G. Bhangal, J. McDaid et al., “Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1β or IL-6,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1167–1179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Izumiya, S. Kim, Y. Izumi et al., “Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling,” Circulation Research, vol. 93, no. 9, pp. 874–883, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-W. Zhang, K. Su, W.-T. Shi et al., “Matrine inhibits the adhesion and migration of BCG823 gastric cancer cells by affecting the structure and function of the vasodilator-stimulated phosphoprotein (VASP),” Acta Pharmacologica Sinica, vol. 34, no. 8, pp. 1084–1092, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Kalluri, “Proteinuria with and without renal glomerular podocyte effacement,” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2383–2389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. P. Scott and S. E. Quaggin, “Review series: the cell biology of renal filtration,” Journal of Cell Biology, vol. 209, no. 2, pp. 199–210, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Alique, E. Civantos, E. Sanchez-Lopez et al., “Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation,” Clinical Science, vol. 127, no. 1, pp. 19–31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. R. J. Johnson, C. E. Alpers, A. Yoshimura et al., “Renal injury from angiotensin II-mediated hypertension,” Hypertension, vol. 19, no. 5, pp. 464–474, 1992. View at Publisher · View at Google Scholar · View at Scopus
  51. M. E. Rosenberg, L. J. Smith, R. Correa-Rotter, and T. H. Hostetter, “The paradox of the renin-angiotensin system in chronic renal disease,” Kidney International, vol. 45, no. 2, pp. 403–410, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Westhoff, B. Serrels, V. J. Fincham, M. C. Frame, and N. O. Carragher, “Src-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling,” Molecular and Cellular Biology, vol. 24, no. 18, pp. 8113–8133, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Ma, A. Togawa, K. Soda et al., “Inhibition of podocyte FAK protects against proteinuria and foot process effacement,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1145–1156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Hla, M.-J. Lee, N. Ancellin, J. H. Paik, and M. J. Kluk, “Lysophospholipids—receptor revelations,” Science, vol. 294, no. 5548, pp. 1875–1878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Rosen and E. J. Goetzl, “Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network,” Nature Reviews Immunology, vol. 5, no. 7, pp. 560–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. M. J. Kluk and T. Hla, “Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors,” Biochimica et Biophysica Acta, vol. 1582, no. 1–3, pp. 72–80, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. M.-J. Lee, S. Thangada, K. P. Claffey et al., “Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate,” Cell, vol. 99, no. 3, pp. 301–312, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. V. Krump-Konvalinkova, S. Yasuda, T. Rubic et al., “Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 3, pp. 546–552, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. E. J. Goetzl and H. Rosen, “Regulation of immunity by lysosphingolipids and their G protein-coupled receptors,” Journal of Clinical Investigation, vol. 114, no. 11, pp. 1531–1537, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Pitson, P. A. B. Moretti, J. R. Zebol et al., “Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation,” The EMBO Journal, vol. 22, no. 20, pp. 5491–5500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Xia, L. Wang, P. A. B. Moretti et al., “Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-α signaling,” The Journal of Biological Chemistry, vol. 277, no. 10, pp. 7996–8003, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. M. L. Allende, M. Bektas, B. G. Lee et al., “Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking,” The Journal of Biological Chemistry, vol. 286, no. 9, pp. 7348–7358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. S.-C. Sensken, C. Bode, and M. H. Gräler, “Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 3, pp. 963–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. H.-M. Ni, X. Chen, Y.-H. Shi et al., “Genetic delineation of the pathways mediated by bid and JNK in tumor necrosis factor-α-induced liver injury in adult and embryonic mice,” The Journal of Biological Chemistry, vol. 284, no. 7, pp. 4373–4382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Z. Huo, B. Wang, Y. K. Liang, Y. Y. Bao, and Y. Gu, “Hepatoprotective and antioxidant effects of licorice extract against CCl 4-induced oxidative damage in rats,” International Journal of Molecular Sciences, vol. 12, no. 10, pp. 6529–6543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Cheung, F. Shen, J. H. Phillips et al., “Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice,” Journal of Clinical Investigation, vol. 121, no. 11, pp. 4446–4461, 2011. View at Publisher · View at Google Scholar · View at Scopus